Last reviewed · How we verify
NCT02300532
Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)
trial testing No intervention in Malignant Glioma in 561 participants. Completed in 24 March 2015.
10 July 2014
Quick facts
| Lead sponsor | Eisai Co., Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 561 |
| Start date | 10 January 2013 |
| Primary completion | 10 July 2014 |
| Estimated completion | 24 March 2015 |
| Sites | 2 locations across Japan |
Drugs / interventions tested
- No intervention
Conditions studied
- Malignant Glioma — all drugs for Malignant Glioma →
Sponsor
Eisai Co., Ltd. — full company profile →
Who can join
Eligibility, any sex, with Malignant Glioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Post-marketing surveillance to investigate the clinical safety and effectiveness in patients of all implantation of Gliadel with malignant glioma in the actual medical setting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02300532
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other recruiting trials for Malignant Glioma
Currently open trials in the same condition.
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07447531 — T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas · NA · recruiting
- NCT06470711 — Mapping of Electrical Properties in the Brain · recruiting
- NCT05717153 — Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma · EARLY_PHASE1 · recruiting
- NCT05030298 — Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial · Phase 1 · recruiting
Other Eisai Co., Ltd. trials
Trials by the same sponsor.
- NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus · Phase 2 · not yet recruiting
- NCT06793709 — A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G · recruiting
- NCT06657378 — A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized T · recruiting
- NCT06322667 — A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab · recruiting
- NCT05633108 — A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02300532 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eisai Co., Ltd.
- Last refreshed: 27 February 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02300532.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing